Skip to content

MaRS Innovation forms third collaboration with Johnson & Johnson Innovation

MaRS Innovation LogoMaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest.

The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615).

This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech.

Earlier this year, Johnson & Johnson Innovation and MaRS Innovation announced their research partnership to advance three technologies focused on improving cardiac surgery outcomes, developing a blood test for depression, and identifying a diagnostic metabolite for both gestational and type 2 diabetes patients. The projects’ principal investigators are researchers from the University Health Network (Peter Munk Cardiac Centre), the Centre for Addiction and Mental Health (with Indoc Research) and the University of Toronto.

“Johnson & Johnson Innovation is an excellent partner that understands exactly the kind of technology pipeline MaRS Innovation represents,” said Dr. Raphael Hofstein, president and CEO. “Renewing their longstanding relationship signals the value they see in this partnership with MaRS Innovation, our members and researchers within our network.”

Continue Reading

Dr. Raphael (Rafi) Hofstein joins Quebec’s CQDM Board of Directors

Dr. Raphael Hofstein
Dr. Raphael Hofstein has joined the Quebec Consortium for Drug Discovery (CQDM) Board of Directors.

MaRS Innovation’s President and CEO, Dr. Raphael (Rafi) Hofstein, was appointed to the Quebec Consortium for Drug Discovery (CQDM) Board of Directors on February 18.

CQDM is a Quebec-based not-for profit that funds and supports joint projects in private and biopharmaceutical sectors.

Here’s an excerpt from CQDM’s announcement:

Dr. Hofstein, actively involved in the field of biotechnology, partnerships and technology transfer for over 30 years, greatly contributed to defining Israel as a world leader in biotechnology. In Israel, Dr. Hofstein held various positions including R & D Manager and Chief of Immunochemistry with the International Genetic Scientific Partnership, Scientific Director at Biotechnological Applications Ltd., Scientific Director and Vice-President, Business Development at Ecogen Inc., prior to becoming President of Mindsense Biosystems Ltd., and then founder, President and CEO, and chairman of the Board of Hadasit Ltd.

CQDM

Dr. Hofstein was also president of BIOMED, the annual biomedical conference of Israel for many years. He was also co-founder and member of the Israeli Life Sciences Industry Organization and co-founder and executive of Israel’s Tech Transfer Network. Dr. Hofstein now serves on various boards, including Life Sciences Ontario, Clinical Trials Ontario as well as the Organizing Committee of the Public Policy Forum on venture capital and innovation. Dr. Hofstein holds a Ph.D. in the life sciences and chemistry, and completed his postdoctoral studies at the Harvard Medical School.

Continue Reading
Back To Top